October 3, 2019 07:23 AM EDT

ADC Therapeutics isn't going public in the US after all, while three other biotech IPOs bring in $319M

ADC Therapeutics is taking a last-minute U-turn at the NYSE after bumping their IPO goal up from $150 million to a potential $200 million …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ADC Ther­a­peu­tics is­n't go­ing pub­lic in the US af­ter all, while three oth­er biotech IPOs bring in $319M